Chronic treatment regimen using glucagon-like insulinotropic peptides

A method of treating a condition selected from the group consisting of hyperglycemia and type 2 diabetes which comprises maintaining chronic steady state plasma levels between about 60 picomoles/liter and about 200 picomoles/liter of a GLP-1 analog or derivative that binds the GLP-1 receptor and is in biologically active form having an in vitro potency within two-fold the in vitro potency of Val8-GLP-1(7-37)OH wherein the GLP-1 analog or derivative is administered by subcutaneous injection to a human subject no more than once or twice every 24 hours.